Companies /Healthcare

Vir Biotechnology Inc

NASDAQ: VIR Biotechnology
$9.96
▼ $2.16 (−17.82%) today
Markets closed · 1:51pm ET

VIR at a Glance

Valuation
Market cap
$1.7B
Profitability
Revenue (TTM)
$302.8M
Profit margin
-61.0%
EPS (TTM)
$-0.97
Price
52-week range
$5 – $14
Street target
$23.38

Headquartered in San Francisco, CA Fiscal year ends December NASDAQ: VIR vir.bio

About Vir Biotechnology

Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company that discovers and develops immune-based medicines for serious infectious diseases and cancer. It currently generates no product revenue.

Its lead infectious disease program is a monthly subcutaneous combination of elebsiran and tobevibart for chronic hepatitis delta. Elebsiran is an HBV-targeting siRNA licensed from Alnylam. Tobevibart is a broadly neutralizing anti-HBsAg monoclonal antibody discovered on Vir's own mAb platform, incorporating Xencor's Xtend half-life technology. The combination is in the pivotal Phase 3 ECLIPSE registrational program (ECLIPSE 1, 2 and 3).

In oncology, Vir holds exclusive rights for oncology and infectious disease to the universal PRO-XTEN masking platform, licensed from Amunix, a Sanofi company. It is developing dual-masked T-cell engagers designed to activate only in the tumor microenvironment:
- VIR-5500 (PSMA), partnered with Astellas, with FDA Fast Track designation for late-line mCRPC and pivotal trials planned for 2027.
- VIR-5818 (HER2).
- VIR-5525 (EGFR).

Vir also has a preclinical oncology portfolio and a collaboration and license agreement with Gilead to engineer three novel PRO-XTEN T-cell engagers. Its other collaboration partners include Norgine. Updated

Latest Activity

VIRVir Biotechnology
Q3 2026
EPS
-$0.57
est -$0.75+23.5%
Revenue
-$188K
est $1M-$2M

Topline data from the pivotal ECLIPSE 1 hepatitis delta trial is due in Q4, a binary event for a $2.0 billion company. Net loss narrowed to $96.3 million as a year-ago milestone expense rolled off, and cash funds operations into the second half of 2028.

Quarterly EPS — reported vs estimate

VIR Coverage

Frequently Asked Questions

What does Vir Biotechnology do?

Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company that discovers and develops immune-based medicines for serious infectious diseases and cancer. It currently generates no product revenue.

What is the VIR stock price target?

The Wall Street consensus 12-month price target for VIR is $23.38.